Experience with Bacillus Calmette-Guerin in Patients with Superficial Bladder Carcinoma
- 1 July 1982
- journal article
- clinical trial
- Published by Ovid Technologies (Wolters Kluwer Health) in Journal of Urology
- Vol. 128 (1), 27-30
- https://doi.org/10.1016/s0022-5347(17)52736-6
Abstract
A randomized study was done on 49 patients with a history of recurrent superficial transitional cell carcinoma of the bladder to determine if the frequency of tumor recurrence could be lessened. The patients were treated with 6 weekly instillations of Tice strain bacillus Calmette-Guerin or thio-tepa, followed by instillations every 2 weeks for 3 months and every month until a recurrence developed or the patients had been treated for 2 years. Twelve additional patients who had previously failed on thio-tepa were placed on the bacillus Calmette-Guerin protocol. There have been no recurrences in the bacillus Calmette-Guerin group, while 9 patients (40 per cent) in the thio-tepa group suffered recurrences. All of the patients treated with bacillus Calmette-Guerin had symptoms of bladder irritability after each instillation. The same type of irritability occurred in 7 patients (25 per cent) in the thio-tepa group. Severe complications occurred in 11 patients treated with bacillus Calmette-Guerin (28 per cent), 4 of whom required hospitalization. Another 12 patients with visible transitional cell carcinoma were treated with weekly instillations of bacillus Calmette-Guerin. Of these patients 6 had total resolution after 18 weekly instillations and 2 had no detectable tumor after 24 weeks of therapy. Two patients were free of tumor after 6 instillations. Of 7 patients with carcinoma in situ treated with weekly instillations of bacillus Calmette-Guerin 5 had complete resolution of the cellular atypia after 18 weeks of therapy. These studies confirm and extend those of others by demonstrating that bladder instillations of bacillus Calmette-Guerin are effective in reducing the recurrence rate in patients with superficial bladder tumor and can eliminate existing tumor in some patients. Symptoms of bladder irritability occur to a varying extent in every patient, and severe systemic toxicity occurred in 28 per cent of the patients.Keywords
This publication has 10 references indexed in Scilit:
- Augmentation of immunity to line 10 hepatoma by BCG. Comparison of different BCG preparationsCancer, 1980
- Immunotherapeutic effectiveness of BCG inactivated by various modalitiesCancer, 1980
- Role of intravesical mitomycin c in management of superficial bladder tumorsUrology, 1980
- Bacillus Calmette-guerin Immunotherapy of Superficial Bladder CancerJournal of Urology, 1980
- Intravesical instillation of adriamycin combined with low-dose irradiation for superficial bladder cancerUrology, 1980
- Adjuvant Therapy of T1 Bladder Carcinoma: Preliminary Results of an EORTC Randomized StudyPublished by Springer Science and Business Media LLC ,1979
- Intracavitary Bacillus Calmette-guerin in the Treatment of Superficial Bladder TumorsJournal of Urology, 1976
- Immunotherapy of guinea pig cancer with bcgCancer, 1974
- Thiotepa Bladder Instillations: Therapy and Prophylaxis for Superficial Bladder TumorsJournal of Urology, 1969
- THIOTEPA IN THE TREATMENT OF TUMOURS OF THE BLADDERThe Lancet, 1961